SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer - Quaterly Results

20 May 2022 Evaluate
The Total revenue for the quarter ended March 2022 of  Rs. 5496.60 millions remain, more or less, the same.Good  Net Profit growth of 25.10% reported above the corresponding previous quarter figure of Rs. 1005.50 millions to Rs. 1257.90 millioins.The company reported a good operating profit of 1825.70 millions compared to 1629.40 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 5496.60 5347.60 2.79 26109.90 22385.50 16.64 26109.90 22385.50 16.64
Other Income 171.20 372.00 -53.98 626.50 811.20 -22.77 626.50 811.20 -22.77
PBIDT 1825.70 1629.40 12.05 8983.80 7932.40 13.25 8983.80 7932.40 13.25
Interest 38.50 35.40 8.76 104.90 151.10 -30.58 104.90 151.10 -30.58
PBDT 1787.20 1594.00 12.12 8878.90 7781.30 14.11 8878.90 7781.30 14.11
Depreciation 336.10 273.10 23.07 1150.00 1094.10 5.11 1150.00 1094.10 5.11
PBT 1451.10 1320.90 9.86 7728.90 6687.20 15.58 7728.90 6687.20 15.58
TAX 193.20 315.40 -38.74 1603.30 1711.10 -6.30 1603.30 1711.10 -6.30
Deferred Tax -95.40 -75.30 26.69 -359.30 -125.20 186.98 -359.30 -125.20 186.98
PAT 1257.90 1005.50 25.10 6125.60 4976.10 23.10 6125.60 4976.10 23.10
Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00
PBIDTM(%) 33.22 30.47 9.01 34.41 35.44 -2.90 34.41 35.44 -2.90

Pfizer Share Price

4849.80 -15.50 (-0.32%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×